Wealth Enhancement Advisory Services’s VanEck Pharmaceutical ETF PPH Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,848	Closed	-$246K	–	3117
2024 Q4	$246K	Buy	+2,848	New	+$258K	﹤0.01%	2542
2024 Q2	–	Sell	-3,151	Closed	-$286K	–	2681
2024 Q1	$286K	Buy	3,151 +151	+5%	+$13.2K	﹤0.01%	1949
2023 Q4	$244K	Hold	3,000	–	–	﹤0.01%	1971
2023 Q3	$240K	Buy	+3,000	New	+$242K	﹤0.01%	1880

Other funds holding PPH

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Wealth Enhancement Advisory Services's PPH Position: Q1 2025 in Review

Wealth Enhancement Advisory Services sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2025, closing a stake of 2,848 shares — an estimated $246K sold.

Wealth Enhancement Advisory Services first reported a position in PPH in Q3 2023 and held it in 4 quarters. The position peaked at $286K in Q1 2024. 136 funds tracked by Wall St. Rank hold PPH as of Q1 2025.

Wealth Enhancement Advisory Services reported no remaining VanEck Pharmaceutical ETF position as of Q1 2025 after selling out during the quarter.
Wealth Enhancement Advisory Services sold 2,848 VanEck Pharmaceutical ETF shares in Q1 2025, an estimated $246K.
Wealth Enhancement Advisory Services first reported a position in VanEck Pharmaceutical ETF in Q3 2023 and held it in 4 quarters.
Wealth Enhancement Advisory Services's VanEck Pharmaceutical ETF position peaked at $286K in Q1 2024.
136 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q1 2025, filed 16 Apr 2025.